Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lev Pavlovsky

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Journal of the American Academy of Dermatology|January 1, 2017
Biologic drug survival in Israeli psoriasis patientsGuy Shalom, Arnon D Cohen, Michael Ziv, et al.
Frontiers in Medicine|July 17, 2023
Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)Stefano Piaserico, Elisabeth Riedl, Lev Pavlovsky, et al.
International Journal of Dermatology|April 10, 2022
Facial demodicosis in the immunosuppressed state: a retrospective case series from a tertiary referral centerIris Amitay-Laish, Efrat Solomon-Cohen, Hana Feuerman, et al.
Dermatology (Basel, Switzerland)|January 27, 2022
The Bacteriology of Skin Lesions in Patients with Hidradenitis Suppurativa Is Associated with Previous Antibiotic Treatment in the Community Setting: A Referral Center ExperienceShira Barmatz, Shira Fisch-Gilad, Asher Hackett, et al.
Acta Dermato-Venereologica|November 26, 2020
Melanoma Risk is Increased in Patients with Mycosis Fungoides Compared with Patients with Psoriasis and the General PopulationShany Sherman, Noa Kremer, Adam Dalal, et al.
Dermatology and Therapy|January 17, 2025
Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) StudyRichard B Warren, Lev Pavlovsky, Antonio Costanzo, et al.
Dermatology and Therapy|November 8, 2024
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) StudyRichard B Warren, Lev Pavlovsky, Antonio Costanzo, et al.
Acta Dermato-Venereologica|September 23, 2020
The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical DataIris Amitay-Laish, Emmanuella Guenova, Pablo L Ortiz-Romero, et al.
Therapeutic Advances in Gastroenterology|November 15, 2021
Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinicHenit Yanai, Hadar Amir Barak, Jacob E Ollech, et al.
Dermatology and Therapy|March 31, 2026
Effectiveness, Quality of Life and Durability of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Real-World Evidence from the PRIMMA StudyIgor Snast, Yuliya Valdman-Grinshpoun, Naji Bathish, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Journal of the American Academy of Dermatology|January 1, 2017
Biologic drug survival in Israeli psoriasis patientsGuy Shalom, Arnon D Cohen, Michael Ziv, et al.
Frontiers in Medicine|July 17, 2023
Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)Stefano Piaserico, Elisabeth Riedl, Lev Pavlovsky, et al.
International Journal of Dermatology|April 10, 2022
Facial demodicosis in the immunosuppressed state: a retrospective case series from a tertiary referral centerIris Amitay-Laish, Efrat Solomon-Cohen, Hana Feuerman, et al.
Dermatology (Basel, Switzerland)|January 27, 2022
The Bacteriology of Skin Lesions in Patients with Hidradenitis Suppurativa Is Associated with Previous Antibiotic Treatment in the Community Setting: A Referral Center ExperienceShira Barmatz, Shira Fisch-Gilad, Asher Hackett, et al.
Acta Dermato-Venereologica|November 26, 2020
Melanoma Risk is Increased in Patients with Mycosis Fungoides Compared with Patients with Psoriasis and the General PopulationShany Sherman, Noa Kremer, Adam Dalal, et al.
Dermatology and Therapy|January 17, 2025
Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) StudyRichard B Warren, Lev Pavlovsky, Antonio Costanzo, et al.
Dermatology and Therapy|November 8, 2024
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) StudyRichard B Warren, Lev Pavlovsky, Antonio Costanzo, et al.
Acta Dermato-Venereologica|September 23, 2020
The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical DataIris Amitay-Laish, Emmanuella Guenova, Pablo L Ortiz-Romero, et al.
Therapeutic Advances in Gastroenterology|November 15, 2021
Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinicHenit Yanai, Hadar Amir Barak, Jacob E Ollech, et al.
Dermatology and Therapy|March 31, 2026
Effectiveness, Quality of Life and Durability of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Real-World Evidence from the PRIMMA StudyIgor Snast, Yuliya Valdman-Grinshpoun, Naji Bathish, et al.
Pageof 6